Hilary Tindle

Dr. Hilary Tindle

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
HTHilary Tindle
Hilary Tindle
PNPaul A Newhouse
Paul A Newhouse
MFMatthew S Freiberg
Matthew S Freiberg

21 July 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
JTJames Gregory Terry
James Gregory Terry
KHKatherine G. Hartley
Katherine G. Hartley
LSLyn Steffen
Lyn Steffen
SNSangeeta Nair
Sangeeta Nair
AAAmy C. Alman
Amy C. Alman
JCJohn Jeffrey Carr
John Jeffrey Carr
Smokers have lower risk of obesity, which some consider a “beneficial” side effect of smoking. However, some studies suggest that smoking is simultaneously associated with higher central adiposity and, more specifically, ectopic adipose deposition. Little is known about the association of smoking with intermuscular adipose tissue (IMAT), an ectopic adipose depot associated with cardiovascular disease (CVD) risk and a key determinant of muscle quality and function. We tested the hypothesis that smokers have higher abdominal IMAT and lower lean muscle quality than never smokers. We measured abdominal muscle total, lean, and adipose volumes (in cubic centimeters) and attenuation (in Hounsfield units [HU]) along with subcutaneous (SAT) and visceral adipose tissue (VAT) volumes using computed tomography (CT) in 3,020 middle-aged Coronary Artery Risk Development in Young Adults (CARDIA) participants (age 42–58, 56.3% women, 52.6% white race) at the year 25 (Y25) visit. The longitudinal CARDIA study was initiated in 1985 with the recruitment of young adult participants (aged 18–30 years) equally balanced by female and male sex and black and white race at 4 field centers located in Birmingham, AL, Chicago, IL, Minneapolis, MN, and Oakland, CA. Multivariable linear models included potential confounders such as physical activity and dietary habits along with traditional CVD risk factors. Current smokers had lower BMI than never smokers. Nevertheless, in the fully adjusted multivariable model with potential confounders, including BMI and CVD risk factors, adjusted mean (95% CI) IMAT volume was 2.66 (2.55–2.76) cm3 in current smokers (n = 524), 2.36 (2.29–2.43) cm3 in former smokers (n = 944), and 2.23 (2.18–2.29) cm3 in never smokers (n = 1,552) (p = 0.007 for comparison of former versus never smoker, and p < 0.001 for comparison of current smoker versus never and former smoker). Moreover, compared to participants who never smoked throughout life (41.6 [41.3–41.9] HU), current smokers (40.4 [39.9–40.9] HU) and former smokers (40.8 [40.5–41.2] HU) had lower lean muscle attenuation suggesting lower muscle quality in the fully adjusted model (p < 0.001 for comparison of never smokers with either of the other two strata). Among participants who had ever smoked, pack-years of smoking exposure were directly associated with IMAT volume (β [95% CI]: 0.017 [0.010–0.025]) (p < 0.001). Despite having less SAT, current smokers also had higher VAT/SAT ratio than never smokers. These findings must be viewed with caution as residual confounding and/or reverse causation may contribute to these associations. We found that, compared to those who never smoked, current and former smokers had abdominal muscle composition that was higher in adipose tissue volume, a finding consistent with higher CVD risk and age-related physical deconditioning. These findings challenge the belief that smoking-associated weight loss or maintenance confers a health benefit.

5 August 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HTHilary Tindle
Hilary Tindle
MFMatthew S. Freiberg
Matthew S. Freiberg
DCDebbie M. Cheng
Debbie M. Cheng
NGNatalia Gnatienko
Natalia Gnatienko
EBElena Blokhina
Elena Blokhina
JSJeffrey H. Samet
Jeffrey H. Samet
The co-occurrence of cigarette smoking and unhealthy alcohol use1 is common2 and detrimental to health.3 Among people with HIV infection, these behaviors are associated with increased risk of non-AIDS diseases.4 Nicotine replacement therapy (NRT) and varenicline, a partial agonist of the α4β2 nicotinic acetylcholine receptor, are effective for smoking cessation, including among individuals with HIV.5-7 Studies among smokers who drink alcohol demonstrate that varenicline reduces alcohol craving and consumption compared with placebo.8,9 Cytisine, a plant-based partial agonist of the α4β2 nicotinic acetylcholine receptor, is effective for smoking cessation10-12 and similar in efficacy to varenicline,13,14 but its effects on alcohol consumption in humans are unknown.15 Converging data support a role of nicotinic acetylcholine receptors in the consumption of alcohol, suggesting that they may serve as pharmacotherapeutic targets to treat risky drinking in addition to their established role in treating smoking.16-19

3 November 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AAAaron W. Aday
Aaron W. Aday
MDMeredith S. Duncan
Meredith S. Duncan
OPOlga V. Patterson
Olga V. Patterson
SDScott L. DuVall
Scott L. DuVall
PAPatrick Raymond Alba
Patrick Raymond Alba
MFMatthew S. Freiberg
Matthew S. Freiberg
Lower-extremity peripheral artery disease (PAD) is common and occurs among 200 million individuals worldwide.1 Patients with PAD are at increased risk of cardiac, cerebrovascular, and limb-related morbidity and mortality.2 Traditional cardiovascular risk factors, including older age,3 smoking,4,5 and diabetes,6,7 are also associated with increased risk of incident PAD.

KSKristina Schnitzer
Kristina Schnitzer
SJSarah Jones
Sarah Jones
JKJennifer H. K. Kelley
Jennifer H. K. Kelley
HTHilary Tindle
Hilary Tindle
NRNancy A. Rigotti
Nancy A. Rigotti
GKGina R. Kruse
Gina R. Kruse
(1) Background: COVID-19 has substantially altered individual environments and behaviors. We aim to explore the impact of COVID-19 on the smoking behavior of individuals trying to quit tobacco. (2) Methods: This study presents a qualitative analysis of individual interviews focused on perceived impacts of the COVID-19 pandemic on tobacco use among 39 participants in the Helping HAND 4 (HH4) post-hospitalization smoking cessation trial (NCT03603496). (3) Results: Emergent impacts of COVID-19 included change in routine, isolation, employment changes, and financial challenges; these in turn were associated with boredom, altered cravings and triggers, and increased stress. The availability of effective coping mechanisms instead of smoking to deal with stress heavily influenced subsequent smoking behavior. These results were triangulated with the Transactional Model of Stress, providing a framework to elucidate connections between factors such as perceived control, self-efficacy, and dispositional coping style, and highlighting potential areas for intervention. (4) Conclusions: Results suggest that stress during the COVID-19 pandemic may undermine effective coping skills among individuals enrolled in a post-hospitalization smoking cessation trial. Strengthening effective coping skills (e.g., minimizing the use of tobacco as a default stress response) and increasing perceived control and self-efficacy are promising intervention targets.

16 April 2020 in Trials
Verified
Journal Article
Open access
PDF file
NRNancy A. Rigotti
Nancy A. Rigotti
KSKristina Schnitzer
Kristina Schnitzer
EDEsa Davis
Esa Davis
SRSusan Regan
Susan Regan
YCYuchiao Chang
Yuchiao Chang
HTHilary Tindle
Hilary Tindle
Background: Tobacco smoking remains the leading preventable cause of death in the US. A hospital admission provides smokers with a unique opportunity to stop smoking because it requires temporary tobacco abstinence while illness may enhance motivation to quit. Hospital interventions must continue post-discharge to increase tobacco abstinence long-term, but how best to accomplish this remains unclear. Building on two previous randomized controlled trials, each of which tested smoking cessation interventions that began in hospital and continued after discharge, this trial compares two interventions that provide sustained smoking cessation treatment after hospital discharge with the goal of improving long-term smoking cessation rates among hospitalized smokers. Methods/design: Helping HAND 4 is a three-site randomized controlled trial that compares the effectiveness of two active interventions for producing validated past 7-day tobacco abstinence 6 months after hospital discharge. Smokers who are admitted to three hospitals receive a standard in-hospital smoking intervention, and those who plan to quit smoking after discharge are recruited and randomly assigned to two interventions that begin at discharge, Personalized Tobacco Care Management (PTCM) or Quitline eReferral. Each lasts 3 months. At discharge, PTCM provides 8 weeks of free nicotine replacement (NRT; a participant’s choice of patch, gum, lozenge, or a combination) and then proactive smoking cessation support using an automated communication platform and live contact with a tobacco treatment specialist who is based in the health care system. In the eReferral condition, a direct referral is made from the hospital electronic health record to a community-based resource, the state’s telephone quitline. The quitline provides up to 8 weeks of free NRT and offers behavioral support via a series of phone calls from a trained coach. Outcomes are assessed at 1, 3, and 6 months after discharge. The study hypothesis is that PTCM will produce higher quit rates than eReferral. Discussion: Helping HAND 4 is a pragmatic trial that aims to evaluate interventions in real-world conditions. This project will give hospital systems critical evidence-based tools for meeting National Hospital Quality Measures for tobacco treatment and maximizing their ability to improve cessation rates and overall health for the millions of smokers hospitalized annually in the US. Trial registration: Prospectively registered prior to start of enrollment at Clinicaltrials.gov, NCT03603496 (July 27, 2018). https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S00084MJ&selectaction=Edit&uid=U00002G7&ts=2&cx=ff0oxn